Rapport Therapeutics Inc Financials
This page shows Rapport Therapeutics Inc (RAPP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Rapport Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Rapport Therapeutics Inc generates $0.78 in operating cash flow (-$87.5M OCF vs -$111.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Rapport Therapeutics Inc's EBITDA was -$124.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 50.9% from the prior year.
Rapport Therapeutics Inc reported -$111.5M in net income in fiscal year 2025. This represents a decrease of 42.4% from the prior year.
Rapport Therapeutics Inc earned $-2.86 per diluted share (EPS) in fiscal year 2025. This represents an increase of 24.3% from the prior year.
Cash & Balance Sheet
Rapport Therapeutics Inc generated -$88.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 31.0% from the prior year.
Rapport Therapeutics Inc held $52.6M in cash against $0 in long-term debt as of fiscal year 2025.
Rapport Therapeutics Inc had 48M shares outstanding in fiscal year 2025. This represents an increase of 30.6% from the prior year.
Margins & Returns
Rapport Therapeutics Inc's ROE was -23.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.6 percentage points from the prior year.
Capital Allocation
Rapport Therapeutics Inc invested $94.8M in research and development in fiscal year 2025. This represents an increase of 55.6% from the prior year.
Rapport Therapeutics Inc invested $616K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 74.4% from the prior year.
RAPP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $22.3M-1.8% | $22.7M+15.9% | $19.6M | N/A | $15.5M-0.9% | $15.7M+25.5% | $12.5M |
| SG&A Expenses | N/A | $7.7M+13.1% | $6.8M-9.6% | $7.5M | N/A | $6.1M+19.3% | $5.1M+11.4% | $4.6M |
| Operating Income | N/A | -$30.0M-1.7% | -$29.5M-8.8% | -$27.1M | N/A | -$21.6M-4.0% | -$20.8M-21.7% | -$17.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$26.9M-0.7% | -$26.7M-11.1% | -$24.1M | N/A | -$17.5M+3.2% | -$18.1M+20.1% | -$22.7M |
| EPS (Diluted) | N/A | $-0.71+5.3% | $-0.75-10.3% | $-0.68 | N/A | $-0.50+70.6% | $-1.70+84.6% | $-11.07 |
RAPP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $512.4M-4.3% | $535.3M+87.5% | $285.5M-5.5% | $302.1M-4.1% | $314.9M-4.9% | $331.1M-4.3% | $346.1M | N/A |
| Current Assets | $498.6M-4.2% | $520.7M+92.7% | $270.2M-7.1% | $291.0M-6.1% | $309.8M-5.0% | $325.9M-4.3% | $340.7M | N/A |
| Cash & Equivalents | $52.6M-79.1% | $251.4M+356.5% | $55.1M-4.4% | $57.6M+1.4% | $56.8M+44.5% | $39.3M-64.3% | $110.2M+48.3% | $74.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $27.8M+17.2% | $23.7M+7.8% | $22.0M+35.6% | $16.2M+70.6% | $9.5M+18.4% | $8.0M-12.8% | $9.2M | N/A |
| Current Liabilities | $19.0M+33.1% | $14.3M+20.5% | $11.9M+26.6% | $9.4M+7.0% | $8.8M+23.5% | $7.1M-12.3% | $8.1M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $484.7M-5.3% | $511.6M+94.2% | $263.5M-7.8% | $285.8M-6.4% | $305.4M-5.5% | $323.1M-4.1% | $336.9M+950.0% | -$39.6M |
| Retained Earnings | -$235.2M-16.8% | -$201.5M-15.4% | -$174.5M-18.1% | -$147.8M-19.4% | -$123.7M-19.3% | -$103.8M-20.3% | -$86.2M | N/A |
RAPP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24.7M-41.4% | -$17.5M+30.3% | -$25.1M-23.9% | -$20.2M-40.1% | -$14.4M+12.0% | -$16.4M-0.4% | -$16.4M+7.2% | -$17.6M |
| Capital Expenditures | $169K+26.1% | $134K+509.1% | $22K-92.4% | $291K+28.8% | $226K+61.4% | $140K-85.5% | $967K-9.8% | $1.1M |
| Free Cash Flow | -$24.9M-41.3% | -$17.6M+29.9% | -$25.1M-22.2% | -$20.5M-39.9% | -$14.7M+11.4% | -$16.6M+4.4% | -$17.3M+7.3% | -$18.7M |
| Investing Cash Flow | -$174.3M-207.0% | -$56.8M-351.3% | $22.6M+7.4% | $21.0M-34.1% | $31.9M+160.2% | -$53.0M+50.5% | -$107.1M-155.5% | -$41.9M |
| Financing Cash Flow | $311K-99.9% | $270.5M+429517.5% | -$63K-1360.0% | $5K-28.6% | $7K+100.5% | -$1.4M-100.9% | $159.4M+150.3% | $63.7M |
| Dividends Paid | N/A | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RAPP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -5.3%+4.9pp | -10.1%-1.7pp | -8.4% | N/A | -5.4%-0.1pp | -5.4% | N/A |
| Return on Assets | N/A | -5.0%+4.3pp | -9.4%-1.4pp | -8.0% | N/A | -5.3%-0.1pp | -5.2% | N/A |
| Current Ratio | 26.17-10.2 | 36.37+13.6 | 22.75-8.3 | 31.01-4.3 | 35.34-10.6 | 45.91+3.8 | 42.08 | N/A |
| Debt-to-Equity | 0.06+0.0 | 0.05-0.0 | 0.08+0.0 | 0.06+0.0 | 0.030.0 | 0.020.0 | 0.03 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Rapport Therapeutics Inc profitable?
No, Rapport Therapeutics Inc (RAPP) reported a net income of -$111.5M in fiscal year 2025.
What is Rapport Therapeutics Inc's EBITDA?
Rapport Therapeutics Inc (RAPP) had EBITDA of -$124.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rapport Therapeutics Inc's return on equity (ROE)?
Rapport Therapeutics Inc (RAPP) has a return on equity of -23.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rapport Therapeutics Inc's free cash flow?
Rapport Therapeutics Inc (RAPP) generated -$88.1M in free cash flow during fiscal year 2025. This represents a -31.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rapport Therapeutics Inc's operating cash flow?
Rapport Therapeutics Inc (RAPP) generated -$87.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Rapport Therapeutics Inc's total assets?
Rapport Therapeutics Inc (RAPP) had $512.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Rapport Therapeutics Inc's capital expenditures?
Rapport Therapeutics Inc (RAPP) invested $616K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Rapport Therapeutics Inc spend on research and development?
Rapport Therapeutics Inc (RAPP) invested $94.8M in research and development during fiscal year 2025.
What is Rapport Therapeutics Inc's current ratio?
Rapport Therapeutics Inc (RAPP) had a current ratio of 26.17 as of fiscal year 2025, which is generally considered healthy.
What is Rapport Therapeutics Inc's debt-to-equity ratio?
Rapport Therapeutics Inc (RAPP) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rapport Therapeutics Inc's return on assets (ROA)?
Rapport Therapeutics Inc (RAPP) had a return on assets of -21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rapport Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Rapport Therapeutics Inc (RAPP) had $52.6M in cash against an annual operating cash burn of $87.5M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rapport Therapeutics Inc's Piotroski F-Score?
Rapport Therapeutics Inc (RAPP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rapport Therapeutics Inc's earnings high quality?
Rapport Therapeutics Inc (RAPP) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.